Abstract
Because Cisplatin potentiates the effect of radiotherapy in animal tumor systems and because Cisplatin is capable of causing regressions of human malignant melanomas, a study was initiated in patients with malignant melanoma metastatic to brain to investigate the feasibility of administering Cisplatin once a week during cranial irradiation.
Cisplatin 40 mg/m2/week (three doses) was given LV. to 18 patients during whole brain irradiation, 3 000 rads in 12 fractions over 2 1/2 weeks. Eleven patients also received Cisplatin 120 mg/m2 every three weeks, starting three weeks after cranial irradiation. Median survival was ten weeks, and only one of 13 patients whose brain metastases had not been resected experienced neurological and CT scan improvement. Thirteen patients have died, and brain metastases were a major cause. No regression of extracerebral tumor was seen in 15 patients with eveluable extracerebral lesions. During weekly low-dose Cisplatin administration, nausea and vomiting were moderate to severe. No granulocytopenia was noted, although three courses were associated with mild thrombocytopenia. Mucositis, peri orbital swelling, vertigo, and headache were each noted in two of 51 courses of treatment and seizures, ototoxicity, pancreatitis, and hiccups were each noted in one course. Renal toxicity and ototoxicity each developed in three of the 11 patients receiving Cisplatin 120 mg/ m2, and nausea and vomiting were severe.
Similar content being viewed by others
References
Withers HR, Harter D: Radiotherapy in the management of malignant melanoma. In: Neoplasms of the skin and malignant melanoma. Year Book Medical Publ, Chicago, 1976, pp 453–561.
Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK: Malignant melanoma and central nervous system metastases. Cancer 42:660–668, 1978.
Goodnight JE Jr, Moseley HS, Eilber FR, Sarna G, Myrton DL: Cis-dichlorodiammineplatinum (II) alone and combined with DTIC for treatment of disseminated malignant melanoma. Cancer Treat Rep 63:2005–2007, 1979.
Chary KK, Higby DJ, Henderson EA, Swinerton KD: A phase I study of high-dose cis-diammine dichloroplatinum (II) with forced diuresis. Cancer Treat Rep 61:367–370, 1977.
Stephens R, Coltman C, Rosof A, Samson M, Panettiere F, Al-Sarraf M, Alberts D, Bonnet J: Cis-dichlorodiammineplatinum (II) in adult patients: Southwest Oncology Group studies. Cancer Treat Rep 63:1609–1610, 1979.
Douple EB, Richmond RC: Platinum complexes as radiosensitizers of hypoxic mammalian cells. Br J Cancer 37 Suppl III:98–102, 1978.
Stewart DJ, Leavens M, Luna M, Seifert W, Loo TL, Benjamin RS: Human central nervous system pharmacology of cis-diamminedichloroplatinum (DDP). Proc Am Soc Clin Oncol 22:359, 1981.
Khan A, McCullough D, Borts F, Sinks LF: Update on use of cis-platinum in CNS malignancies. Proc Am Soc Clin Oncol 21:390, 1980.
Rozencweig M, Von Hoff DD, Slavik M, Muggia FM: Cis-diammined ichloroplatinum (II): a new anticancer drug. Ann Intern Med 86:803–812, 1977.
Reimer RR, Gahbauer R, Bukowski R, Hewlett J, Groppe C, Weick J: Simultaneous radiation therapy (RT) and cisplatinum (CDDP) chemotherapy for human solid tumors: a pilot study. Proc Am Soc Clin Oncol 21:397, 1980.
Stewart, DJ, Benjamin, RS, Luna M, Yeung K, Leavens M, Feun L, Yap HY, Loo TL: Human tissue vinblastine (V) and cosplatin (CP). Proc Am Assoc Cancer Res 23:125, 1982.
Costanza M, Nathanson L Schoenfeld D, Walter J, Colsley J, Regelson W, Cunninbgham T, Sedransk N: Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 40:1010–1015, 1977.
Warren RD, Bender RA: Drug interactions with antineoplastic agents. Cancer Treat Rep 61:1231–1241, 1977.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stewart, D.J., Feun, L.G., Maor, M. et al. Weekly Cisplatin during cranial irradiation for malignant melanoma metastatic to brain. J Neuro-Oncol 1, 49–51 (1983). https://doi.org/10.1007/BF00153641
Issue Date:
DOI: https://doi.org/10.1007/BF00153641